Free Trial
NASDAQ:MBIO

Mustang Bio Q2 2025 Earnings Results & Report

Mustang Bio logo
$0.40 -0.02 (-4.05%)
As of 10/9/2026 04:00 PM Eastern

Mustang Bio reported Q2 2025 earnings on August 8, 2025. The company reported EPS of -$0.19.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
After Market Closes
Conference Call
4:00 PM ET

Mustang Bio EPS Results

Actual EPS
-$0.19
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 4 quarters

Mustang Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Mustang Bio's Q3 2026 earnings is estimated for Wednesday, November 18, 2026, based on past reporting schedules

Earnings Documents

Mustang Bio Q2 2025 Earnings FAQ

Mustang Bio (NASDAQ:MBIO) reported earnings of -$0.19 per share for Q2 2025. The report was announced on Friday, August 8, 2025.

Mustang Bio's next earnings date is estimated for Wednesday, November 18, 2026. MarketBeat tracks confirmed and estimated earnings dates for Mustang Bio on the company's earnings history page.

Mustang Bio Earnings Headlines

No. 1 stock to cash in on the death of iPhone
Analyst Josh Baylin, who warned Congress about smartphones years before the iPhone launched, says the world's richest man may be building an iPhone rival he calls Starphone. Baylin points to FCC rulings, two trademarks filed the same day, multibillion-dollar spectrum deals, chip partnerships, and a string of posts from Elon Musk as evidence pointing to one conclusion. See the full research and the stock Baylin is watching now.tc pixel
Mustang Bio Inc.
See More Mustang Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Mustang Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mustang Bio and other key companies, straight to your email.

About Mustang Bio

Mustang Bio (NASDAQ:MBIO) is a clinical-stage biotechnology company focused on developing cell and gene therapies for cancer and other serious diseases. The company has historically operated as a subsidiary of Fortress Biotech and has concentrated on engineered T-cell therapies designed to recognize and attack specific tumor targets.

Its development programs have included MB-106, an investigational CD20-targeted CAR T-cell therapy for certain B-cell malignancies, and MB-101, an investigational CAR T-cell therapy targeting IL13Rα2 for glioblastoma and other central nervous system tumors. Mustang Bio has also pursued related next-generation and combination approaches intended to improve the persistence, safety, or effectiveness of these therapies.

Mustang Bio’s programs have primarily been developed through research and clinical collaborations in the United States, including relationships with academic and medical institutions. The company’s therapies remain investigational and have not been established as approved commercial products. Mustang Bio was founded in 2015 and has historically been led by executives with experience in biotechnology, oncology, and cell therapy development.

View Mustang Bio Profile